SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated securities laws and engaged in unlawful business practices in connection with its initial public offering ("IPO"). Poseida is a clinical-stage biopharmaceutical company that develops therapeutics for patients with high unmet medical needs.
If you have suffered a loss due to Poseida Therapeutics, Inc.'s misconduct, click here.
Poseida conducted its IPO on July 10, 2020, issuing 14 million shares for $16.00 per share. On August 18, 2020, Poseida announced that the U.S. Food and Drug Administration had placed a clinical hold on its Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer due to a patient's death. On this news, Poseida's stock fell 30.31%, to close at $9.06 on August 18, 2020.
Poseida Therapeutics, Inc. (PSTX) Shareholders Have Legal Options
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Poseida settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
